INTRODUCTION
Multiple Sclerosis (MS) is a common, heterogeneous disorder of the central nervous system (CNS). Its causes and the factors that contribute to its heterogeneity are largely unknown. The disease affects about 0.1 percent of the population in temperate climates (approximately 1.4 million people worldwide) [1] . It is a disease of young people (median age of onset is approximately 28 years) but is lifelong and is often disabling
In multiple sclerosis, the immune system attacks the brain's nerve fibers and strips away the protective myelin sheath around nerve fibers in the spinal cord and brain. The resulting lesions make it difficult for the nerves to transmit messages.
The cause of MS is not known. Epidemiological findings support both environmental and genetic hypotheses, and these forces likely interact to produce individual disease susceptibility and influence disease course.
CELL REPLACEMENT AS A SOLUTION TO MS
A treatment dilemma posed by MS is how to restore nerve-insulating myelin after it is destroyed by the body's immune system. Because this immune response also induces the death of oligodendrocytes, the myelin-making cells in the brain and spinal cord, spontaneous remyelination is insufficient. One of the most exciting areas of MS research is the effort to transplant myelin-making cells into the central nervous system. These cells may be able to repair damage to myelin, regenerate injured axons and restore nerve signal conduction. The This trial is being designed to determine if these cells can survive and to make sure treatment is safe. The procedure will be attempted one person at a time, and if there are any problems, the study will be stopped. If safety and tolerability of this invasive procedure can be shown, clinical trials to test its effectiveness will be planned which involve larger numbers of people and a well-controlled design.
The first central nervous system transplantation to repair the myelin-forming cells in MS was carried out on a woman with MS. The procedure took place on July 17 and 18 of 2001. In the first 24 hours, the team isolated the Schwann cells from the sural nerve, which was removed from the patient's ankle. A neurosurgery team led by Dr. Dennis Spencer (Professor and Chairman of Neurosurgery) then performed stereotactic surgery on the patient, using an magnetic resonance imaging) machine to very accurately guide a needle through the frontal lobe and inject the Schwann cells into a previously identified MS lesion.
Dr. Vollmer says the patient was then studied using a number of techniques, including neuroimaging and functional assessments for six months. At the end of that period, the team used a stereotactic procedure to take a small biopsy to determine whether the cells survived and whether they made any myelin.
A 29-year-old man with MS was the second patient to undergo this procedure. down with adrenoleukodystrophy (ALD), a rare inherited disease, in which the myelin sheath is destroyed. Doctors said that he would lose all his functions and die within two to three years. Refusing to accept this grim verdict, the Odones set out on a mission to find a treatment for ALD and to save their child (Lorenzo survived and is now 23 years old). In their quest for a treatment, the Odones often clashed with doctors, scientists, and support groups, who were skeptical that anything could be done about ALD, much less by lay people. The Odones haunted medical libraries, reviewed countless animal experiments, badgered researchers, questioned top doctors all over the world, and persisted until a solution came to them in a moment of inspiration. They commissioned a special type of oil (oleic acid and erucic acid) from a British firm, which normalized the accumulation of very long chain fatty acids in the blood of ALD boys. This allowed Lorenzo and others to live on a restricted diet.
In the second chapter of the story, the Odones founded The Myelin Project in the hope of finding a way to restore the myelin sheath, which is destroyed in ALD and a host of other myelin diseases, such as multiple sclerosis.
For the millions affected by MS, the groundbreaking Schwann cell replacement therapy attempted by Dr. Vollmer's team at Yale is a cautious step towards a better life.
